Skip to main content
Premium Trial:

Request an Annual Quote

Gilead Licenses Aptamer IP to Start-Up Biotech Firm Archemix

NEW YORK, Nov. 6 – Gilead Sciences has sold an exclusive license to its aptamer-based IP for $17.5 million to Archemix, a privately held biotechnology company based in Cambridge, Mass., the company announced on Tuesday.

The deal, which Archemix said will complement its existing aptamer IP, gives the company “a broad spectrum” of DNA-based tools that it plans to use in drug discovery and development, it said.

“Based on this technology, we are developing platforms that can be used both in vitro and in vivo to take a snapshot of the level and state of all major networks of proteins inside a cell,” Martin Stanton, president of Archemix, said in a statement. 

Financial terms of the deal, which also allows Archemix to sub-license the aptamer IP, were not disclosed.

Archemix said it has already developed aptamer-based tools to perform both in vitro and in vivo multiplex assays that it claims can monitor several pathways or proteins in a single assay. The company, which was founded in May, said it will use this technology to develop “novel screens” to help researchers evaluate the specificity and potential toxicity of new compounds early on in the drug-discovery process.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.